Nanomedical Diagnostics Announces Peer Reviewed Publication

Nanomedical Diagnostics, a Serra Capital II portfolio company, made a major announcement on October 11. Nano, the biotech company driving the use of label-free graphene biosensor assays in life science research and diagnostics, announced a publication titled “Large Scale Commercial Fabrication of High Quality Graphene-Based Assays for Biomolecule Detection” in the journal Sensors & Actuators B: Chemical. 

The publication describes the company’s translation of Nobel Prize-winning nanoscience into standard electronics assembly processes to manufacture AGILE R100, a new benchtop assay built on break-through field effect biosensing technology.